Pharma BD Deal Intelligence
Regeneron expanded its bispecific antibody collaboration with CytomX, unlocking $37M in near-term nomination payments and up to $4B in total potential milestones for adding eight new PROBODY-masked programs. The deal deepens Regeneron's pipeline in tumor-localized bispecifics without any upfront cash outlay disclosed beyond the nomination fees.
Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact. Regeneron expanded its research alliance with CytomX Therapeutics, paying $37 million to work…
CytomX and Regeneron Expand Collaboration on Tumor-Activated Bispecific Cancer Therapies. The collaboration combines CytomX's Probody masking platform with…
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics. Regeneron Pharmaceuticals broadened its partnership with clinical-stage oncology company…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
On June 3, 2026, CytomX Therapeutics announced an expansion of its strategic research collaboration with Regeneron to develop conditionally-activated bispecific antibody cancer therapies, combining CytomX's PROBODY tumor-localization (masking) technology with Regeneron's Veloci-Bi bispecific platform. The expansion was effected through Amendment No. 4 to the companies' November 16, 2022 Collaboration and License Agreement, signed May 29, 2026 and effective May 31, 2026, which extends the program-selection period and provides for the addition of up to eight additional collaboration programs. Regeneron nominated the first two additional programs, entitling CytomX to aggregate target nomination payments of $37.0 million; the remaining six programs are subject to Regeneron's nomination option and per-program fees. Across the expanded collaboration CytomX is eligible for up to approximately $4 billion in target nomination, preclinical, clinical, regulatory and commercial milestone payments, plus tiered royalties (unchanged by the amendment). Regeneron funds and leads preclinical and clinical development and commercialization; CytomX contributes discovery and its masking technology.
The collaboration develops conditionally-activated (tumor-localized) bispecific antibodies for solid-tumor oncology, combining CytomX's PROBODY masking technology — which keeps an antibody inactive until proteolytically activated in the tumor microenvironment — with Regeneron's Veloci-Bi bispecific platform, aiming to widen the therapeutic window of potent T-cell-engaging and other bispecific formats. Specific antigen targets are undisclosed.
Expansion of the companies' 2022 research collaboration: two additional targets selected (triggering a $37M nomination payment to CytomX) with options for up to six more. Regeneron funds and leads preclinical/clinical development and commercialization; CytomX contributes discovery and masking technology. Up to ~$4B in milestones plus royalties to CytomX. No clinical candidate disclosed under the expansion.
Regeneron and CytomX expanded their strategic research collaboration on conditionally-activated bispecific antibody cancer therapies (CytomX PROBODY + Regeneron Veloci-Bi). Two additional targets were selected, triggering a $37M nomination payment to CytomX, with options for up to six more targets and up to ~$4B in milestones plus royalties. Regeneron leads and funds development and commercialization.
Per CytomX's Form 8-K, the expansion was effected through Amendment No. 4 to the November 16, 2022 Collaboration and License Agreement (signed May 29, 2026; effective May 31, 2026). The amendment is in force: Regeneron nominated the first two of up to eight additional programs, triggering $37.0M in target nomination payments to CytomX, with up to ~$4B total potential milestones plus royalties. No regulatory close is pending for a research-collaboration amendment.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. / CytomX Therapeutics, Inc. (this deal) | 2026 | $4.0B | 62 |
| Regeneron Pharmaceuticals, Inc. / Alnylam Pharmaceuticals Inc. | 2019 | $1.0B | 77 |
| Regeneron Pharmaceuticals, Inc. / Sanofi S.A. (Libtayo global rights) | 2022 | $1.1B | — |
| Regeneron Pharmaceuticals, Inc. / 23andMe, Inc. | 2025 | $256M | — |
| Regeneron Pharmaceuticals, Inc. / Parabilis Medicines, Inc. | 2026 | $2.3B | — |
| Regeneron Pharmaceuticals, Inc. / Telix Pharmaceuticals Limited | 2026 | $2.1B | — |
| Regeneron Pharmaceuticals, Inc. / Tessera Therapeutics, Inc. | 2025 | $275M | — |
← Browse all deals · How we score deals
More: 2026 deals · Regeneron Pharmaceuticals, Inc. deals · Oncology deals